LMO2 and gene therapy for severe combined immunodeficiency [7] (multiple letters)

New England Journal of Medicine

Volumn 350, Issue 24, 2004, Pages 2526-2527

  Fischer, Alain ^a   Hacein Bey Abina, Salima ^a   Thrasher, Adrian ^b   Von Kalle, Christof ^c   Cavazzana Calvo, Marina ^a   Stone, Bryan D ^d   Rabbitts, Terence H ^e   McCormack, Matthew P ^f  

^a INSERM   (France)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^f Rotary Bone Marrow Res Laboratories   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; CYTOKINE RECEPTOR; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 21; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 9 RECEPTOR; INTERLEUKIN RECEPTOR; T LYMPHOCYTE RECEPTOR; INTERLEUKIN 2;

COMBINED IMMUNODEFICIENCY; DISEASE SEVERITY; ENZYME DEFICIENCY; GENE THERAPY; HUMAN; LETTER; LYMPHOCYTE DIFFERENTIATION; LYMPHOPOIESIS; NATURAL KILLER CELL; ONCOGENE; ONCOGENE LMO2; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; X CHROMOSOME LINKED DISORDER; AGE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NOTE; PHYSIOLOGY; VIRUS ACTIVATION; B LYMPHOCYTE; IMMUNOLOGY;

AGE FACTORS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC DISEASES, X-LINKED; HUMANS; INTERLEUKIN-2; ONCOGENES; RECEPTORS, INTERLEUKIN-2; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES; VIRUS ACTIVATION; ADENOSINE DEAMINASE; B-LYMPHOCYTES; KILLER CELLS, NATURAL; PHENOTYPE; RECEPTORS, INTERLEUKIN;

EID: 2942560458     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200406103502422     Document Type: Letter

References (0)